WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTC: ACTC) announced today that an Irish institutional investor has increased its funding commitment to the Company by $500,000. Transition Holdings, Inc, which has already provided an additional $150,000 in funding, has increased its total commitment under which it will purchase a total of $1 million of one-year 7% convertible debentures over the next six months. The Company will use the proceeds for working capital, general corporate purposes and to continue the development of its most advanced clinical programs. The Company continues to negotiate with partners to jointly develop its pre-clinical and certain clinical programs in heart failure, retinal disease and the production of red blood cells.
